Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients

医学 钙通道阻滞剂 血管紧张素受体 肾功能 药理学 内科学 泌尿科 血管紧张素II 受体
作者
Michihiro Satoh,Takuo Hirose,Hironori Satoh,Shinichi Nakayama,Taku Obara,Takahisa Murakami,Tomoko Muroya,Kei Asayama,Masahiro Kikuya,Takefumi Mori,Yutaka Imai,Takayoshi Ohkubo,Hirohito Metoki
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins]
卷期号:40 (8): 1564-1576 被引量:2
标识
DOI:10.1097/hjh.0000000000003186
摘要

Objective: This observational retrospective cohort study investigates the effect of antihypertensive therapy with angiotensin II receptor blockers (ARBs) or dihydropyridine calcium channel blockers (dCCBs) monotherapy on renal function using longitudinal real-world health data of a drug-naive, hypertensive population without kidney disease. Methods: Using propensity score matching, we selected untreated hypertensive participants ( n = 10 151) and dCCB ( n = 5078) or ARB ( n = 5073) new-users based on annual health check-ups and claims between 2008 and 2020. Participants were divided by the first prescribed drug. Results: The mean age was 51 years, 79% were men and the mean estimated glomerular filtration rate (eGFR) was 78 ml/min per 1.73 m 2 . Blood pressure rapidly decreased by approximately 10% in both treatment groups. At the 1-year visit, eGFR levels decreased in the ARB group by nearly 2% but increased in the dCCB group by less than 1%. However, no significant difference was apparent in the annual eGFR change after the 1-year visit. The risk for composite kidney outcome (new-onset proteinuria or eGFR decline ≥30%) was lowest in the ARB group owing to their robust effect on preventing proteinuria: hazard ratio (95% confidence interval) for proteinuria was 0.91 (0.78–1.05) for the dCCB group and 0.54 (0.44–0.65) for the ARB group, compared with that for the untreated group after ending follow-up at the last visit before changing antihypertensive treatment. Conclusion: From the present findings based on the real-world data, ARBs can be recommended for kidney protection even in a primary care setting. Meanwhile, dCCB treatment initially increases eGFR with no adverse effects on proteinuria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
111发布了新的文献求助20
1秒前
声声慢发布了新的文献求助10
1秒前
炙热怜寒完成签到,获得积分10
2秒前
2秒前
Adzuki0812完成签到,获得积分10
2秒前
科目三应助澡雪采纳,获得10
3秒前
桐桐应助仁爱樱采纳,获得10
3秒前
不吃西瓜发布了新的文献求助10
3秒前
思源应助胖橘梨花逻辑猫采纳,获得10
4秒前
4秒前
李爱国应助啊啊啊啊采纳,获得10
4秒前
张海桐发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
5秒前
科目三应助fc小肥杨采纳,获得10
6秒前
7秒前
li发布了新的文献求助50
8秒前
高高代萱发布了新的文献求助10
8秒前
风趣的老太应助15858833895采纳,获得10
8秒前
英俊的铭应助帕荣荣采纳,获得10
9秒前
9秒前
9秒前
汉堡包应助Yukangqian采纳,获得10
11秒前
心灵美从寒完成签到,获得积分10
11秒前
安澜发布了新的文献求助30
12秒前
12秒前
啊啊发布了新的文献求助10
12秒前
slby完成签到 ,获得积分10
13秒前
大力的寻琴完成签到,获得积分10
14秒前
16秒前
玛卡巴卡发布了新的文献求助10
16秒前
啊啊啊啊发布了新的文献求助10
17秒前
ding应助Queena采纳,获得10
17秒前
韩涵发布了新的文献求助10
18秒前
飞翔的梦完成签到,获得积分10
18秒前
18秒前
BBIBBI完成签到,获得积分10
19秒前
共享精神应助liu采纳,获得10
19秒前
QL发布了新的文献求助10
19秒前
声声慢完成签到,获得积分10
21秒前
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975871
求助须知:如何正确求助?哪些是违规求助? 3520207
关于积分的说明 11201502
捐赠科研通 3256611
什么是DOI,文献DOI怎么找? 1798403
邀请新用户注册赠送积分活动 877552
科研通“疑难数据库(出版商)”最低求助积分说明 806430